Trezix description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Trezix

WraSer LLC

TREZIX™ Capsules




FULL PRESCRIBING INFORMATION

Acetaminophen, Caffeine and Dihydrocodeine Bitartrate           CIII

320.5 mg / 30 mg / 16 mg
Rx Only

Hepatotoxicity

DESCRIPTION:






*Warning: may be habit-forming.



Trezix


Trezix


Trezix

CLINICAL PHARMACOLOGY:


Uses

INDICATIONS AND USAGE:

CONTRAINDICATIONS:

WARNINGS:
Hepatotoxicity:






Hypersensitivity/Anaphylaxis:


Usage in Ambulatory Patients:


Respiratory Depression:


Head Injury:


Hypotensive Effect:



Drug Dependence:
DRUG ABUSE AND DEPENDENCE
PRECAUTIONS:
General:
DOSAGE AND ADMINISTRATION

Drug Interactions:
Dihydrocodeine with Other Central Nervous System Depressants:


Dihydrocodeine with Monoamine Oxidase Inhibitors:


Dihydrocodeine with Mixed Agonist/Antagonist Opioid Analgesics:


Acetaminophen Drug Interactions:



Caffeine Drug Interactions:

Information for Patients/Caregivers:










Pregnancy:

Labor and Delivery:

Nursing Mothers:

Pediatric Use:

Geriatric Use:
TREZIX™ capsules should be given with caution to the elderly.

Hepatic Impairment:
TREZIX™ capsules should be given with caution to patients with hepatic insufficiency. Since dihydrocodeine is metabolized by the liver and since acetaminophen potentially causes hepatotoxicity, the effects of this combination product should be monitored closely in such patients.

Renal Impairment:
TREZIX™ capsules should be used with caution and at reduced dosage in the presence of impaired renal function.

Pancreatic/Biliary Tract Disease:

ADVERSE REACTIONS:
Dihydrocodeine:


Acetaminophen:
OVERDOSAGE

Caffeine:

DRUG ABUSE AND DEPENDENCE:


OVERDOSAGE:


Signs and Symptoms: dihydrocodeine

acetaminophen caffeine



Treatment







DOSAGE AND ADMINISTRATION:

HOW SUPPLIED:








Rx Only

Manufactured for:






WraSer TM
PHARMACEUTICALS

NDC 66992-340-10

TREZIX® CIII

(acetaminophen, caffeine and dihydrocodeine*
bitartrate capsules 320.5mg/30mg/16mg)

Hepatotoxicity
Acetaminophen has been associated with cases of acute liver
failure, at times resulting in liver transplant and death. Most of
the cases of liver injury are associated with the use of acetaminophen
at doses that exceed 4000 milligrams per day, and often
involve more than one acetaminophen containing product.

Rx ONLY

*WARNING: May be habit-forming.

100 CAPSULES

Trezix

Trezix

acetaminophen, caffeine, dihydrocodeine bitartrate CAPSULE

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:66992-340
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ACETAMINOPHEN ACETAMINOPHEN 320.5 mg
CAFFEINE 30 mg
Dihydrocodeine Bitartrate DIHYDROCODEINE 16 mg

Inactive Ingredients

Ingredient Name Strength
CROSPOVIDONE
MAGNESIUM STEARATE
povidone
STARCH, CORN
STEARIC ACID

Product Characteristics

Color Size Imprint Code Shape
red 20 mm TREZIX CAPSULE

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:66992-340-10 100 in 1 BOTTLE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA040688 2009-09-01


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.